Adverse Event reporting information can be found in footer

Unique among 5-ASAs, only PENTASA® has ethyl cellulose coated microgranules.3-18

These consistently release mesalazine throughout the whole colon at all enteral pH conditions, independent of food co-administration.3-6

Request a Meeting

Unique among 5-ASAs, only PENTASA® has ethyl cellulose coated microgranules.3-18

 

These consistently release mesalazine throughout the whole colon at all enteral pH conditions, independent of food co-administration.3-6

 

Artboard-23Kid1Sidebar-1
Artboard-23Kid1Sidebar-1

Prescribe PENTASA® for your paediatric* patients because:

  • PENTASA® demonstrated complete remission† in mild to moderate paediatric* UC patients at week 61
  • The formulations include 1g, 2g and 4g sachets, which may reduce pill burden and encourage patient adherence2, 4-6
  • 89% of paediatric* patients were found to be compliant to therapy at week 6 of a randomised controlled trial1
  • PENTASA® can be taken independent of food or in yoghurt at any time of the day to fit in with your paediatric* patients’ daily routine, making them more convenient than ever4-6

*PENTASA® (500mg tablets, 1g, 2g and 4g sachets) is licensed in children 6 years of age and older, and given in divided doses.
†Complete remission was defined as remission (PUCAI<10 points) and a change of at least 10 points from baseline.

  • Turner D, et al. J Crohn’s Colitis. 2017;11:527–533.
  • Ye B and van Langenberg DR. World J Gastrointest 
PharmacolTher.2015;6(4):137-144.
  • Pentasa Slow Release Tablets 500 mg. SmPC.
  • Pentasa Sachet 1 g. SmPC.
  • Pentasa Sachet 2 g. SmPC.
  • Pentasa Sachet 4 g. SmPC.
  • Salofalk 250 mg MR Tablets. SmPC.
  • Salofalk 500 mg Tablets. SmPC.
  • Salofalk 500 mg Gastro-resistant Prolonged Release Granules. SmPC.
  • Salofalk 1 g Tablets. SmPC.
  • Salofalk 1 g Gastro-resistant Prolonged Release Granules. SmPC.
  • Salofalk 1.5 g Gastro-resistant Prolonged Release Granules. SmPC.
  • Salofalk 3 g Gastro-resistant Prolonged Release Granules. SmPC.
  • Sulfasalazine 250 mg/5 ml Oral Suspension. SmPC.
  • Octasa 400 mg MR Tablets. SmPC.
  • Octasa 800 mg MR Tablets. SmPC.
  • Salazopyrin Tablets. SmPC.
  • Salazopyrin En-Tabs. SmPC.
Efficacy in Paediatrics
Compliance in Paediatrics
Paediatric Formulations
Pentasa in Adults
Resources

Job Code: UK-PA-2000023 - Date of preparation: October 2020

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.